Plus, genetically engineered babies, antidepressant misconceptions and the first new malaria drug in years, in this issue of ...

Prices are falling for the popular obesity treatments Wegovy and Zepbound, but steady access to the drugs remains challenging ...

Analysts also weigh in on Chesapeake Utilities, Halozyme Therapeutics, Sea Ltd., and Roper Technologies. Trump reverses on tariffs for some imports, Bitcoin falls on details of strategic reserve, ...

This expansion into diagnostics and tailored care represents a logical strategic extension of the company's telehealth model. Yet, the market's focus remained fixed on the worrying traffic and ...

Novo Nordisk and Eli Lilly denied weight-loss drug partnership with Mangoceuticals on Thursday, hours after the telehealth ...

Hims & Hers Health’s ($HIMS) shares continued to plunge on Thursday despite the consumer telehealth company launching a new ...

Hims & Hers Health (HIMS) stock is in focus as the firm launches Labs, a product offering preventive care through insights ...

After a tumultuous year, a popular virtual care platform is trying its hand in a competitive blood testing market.

WeightWatchers' CEO said on Wednesday it planned to offer Novo Nordisk's much-anticipated Wegovy in pill form if it is ...

How Ozempic Is Changing Thanksgiving According to the independent research and polling source KFF, one in eight Americans reported taking a GLP-1 receptor agonist ...

Shares of Mangoceuticals surged 28% ‌to $2.25 in premarket trading. U.S. regulations allow compounding pharmacies to copy ...

Hims & Hers Health finds itself navigating a complex financial landscape. The telehealth specialist is demonstrating remarkable revenue expansion while s ...